Aardvark is a clinical stage biopharmaceutical company focused on the development and commercialization of safe and effective small molecule therapeutics that have broad therapeutic potential.

Their lead product, ARD-101, is a first-in-class oral drug that has low systemic exposure (gut-restricted) which contributes to its safety, yet conveys systemic effects via activation of gut peptide hormone secretion and gut-brain signaling. Preclinical and human clinical data support a broad safety window with efficacy in several metabolic and inflammatory disease models. Initial clinical trial results have recapitulated the activity seen preclinical studies and support continued development.